Osteoporosis in the rheumatic disease patient

Lupus

Volumn 11, Issue 10, 2002, Pages 675-679

  Lane, N E ^a   Rehman, Q ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone loss; Rheumatology patients

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

ARTHRITIS; BONE REMODELING; CONFERENCE PAPER; HUMAN; INFLAMMATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; TISSUE INJURY;

ANIMALS; ARTHRITIS; BONE REMODELING; BONE RESORPTION; HUMANS; OSTEOPOROSIS; RHEUMATIC DISEASES;

EID: 0036029872     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu261oa     Document Type: Conference Paper

References (56)

1. Eggelmeijer F, Papapoulos SE, Westedt ML, Van Paassen HC, Dijkmans BA, Breedveld FC. Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993; 32: 87-91.
2. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford) 1999; 38: 21-27.
3. Mellish RW, O'Sullivan MM, Garrahan NJ, Compston JE. Iliac crest trabecular bone mass and structure in patients with non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1987; 46: 830-836.
4. Hanson CA, Shagrin JW, Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthoped 1971; 74: 59-64.
5. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000; 43: 522-530.
6. Toussirot E, Michel F, Auge B, Wendling D. Bone mass, body composition and bone ultrasound measurements in Ankylosing spondylitis. Arthritis Rheum 1999; 42(Suppl): S356.
7. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F, Roig-Escoret D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995; 54: 274-276.
8. Lee SK, Goldring SR, Lorenzo JA. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: A specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology 1995; 136: 4572-4581.
9. Faust J, Lacey DL, Hunt P et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 1999; 72: 67-80.
10. Hattersley G, Chambers TJ. Calcitonin receptors as markers for osteoclastic differentiation: Correlation between generation of boneresorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology 1989; 125: 1606-1612.
11. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998; 93: 165-176.
12. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
13. The American Society for Bone and Mineral Research President's Committee on Nomenclature. Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J Bone Miner Res 2000; 15: 2293-2296.
14. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev 1992; 13: 66-80.
15. Ross FP, Chappel J, Alvarez JI et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 1993; 268: 9901-9907.
16. Vaananen HK, Horton M. The osteoclast clear zone is a specialized cell - Extracellular matrix adhesion structure. J Cell Sci 1995; 108: 2729-2732.
17. Kong YY, Feige U, Sarosi I et al. Activaled T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
18. Suzuki Y, Nishikaku F, Nakatuka M, Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 1998; 25: 1154-1160.
19. Pettit AR, Ji H, von Strechow D et al. TRANCE/RANKL knowckout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159: 1689-1699.
20. Gravallese EM, Goldring SR. Cellular mechanism and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2143-2151.
21. Kontoyiannis D, Kollian G. Fibroblast biology: Synovial fibrolbasts in rheumatoid arthritis: Leading role or chorus line? Arthritis Res 2000; 2: 342-343.
22. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250-258.
23. Takayanagi H, lizuka H, Juji T et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259-269.
24. Illei GG, Lipsky PE. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr Opin Immunol 2000; 12: 712-718.
25. Rehman Q, Lane NE. Therapeutic approaches for preventing inflammatory bone loss in inflammatory arthritis. Arthritis Res 2001; 3: 221-227.
26. Kobayashi K, Takahashi N, Jimi E et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-286.
27. Redlich K, Hayer S, Maier A et al. Tumor necrosis factor alphamediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785-792.
28. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989; 125: 1142-1150.
29. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983; 306: 378-380.
30. Dinarello CA. The inteleukin-1 family: 10 Years of discovery. FASEB J 1994; 8: 1314-1325.
31. Kimble RB, Vannice JL, Bloedow DC et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994; 93: 1959-1967.
32. Jimi E, Nakamura I, Duong LT et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999; 247: 84-93.
33. Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest 1999; 103: 1409-1418.
34. Jiang Y, Genant HK, Watt I et al. A multicenter, double-blind, doseranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-1009.
35. Ishimi Y, Miyaura C, Jin CH et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297-3303.
36. Manolagas SC. Role of cytokines in bone resorption. Bone 1995; 17(2 Suppl): 63S-67S.
37. De Benedetti F, Massa M, Pignatti F, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114-2119.
38. Gaillard JP, Bataille R, Brailly H et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993; 23: 820-824.
39. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998; 20: 247-259.
40. Gracie JA, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104: 1393-1401.
41. Micallef MJ, Ohtsuki T, Kohno K et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26: 1647-1651.
42. Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 1999; 162: 1096-1100.
43. Yudoh K, Matsuno H, Osada R, Nakazawa F, Katayama R, Kimura T. Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients. Arthritis Rheum 2000; 43: 2178-2188.
44. Zeidler HK, Kvien TK, Hannonen P et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: Comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998; 37: 874-882.
45. Sham JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide. Rheumatoid Arthitis Investigators Group. Arthritis Rheum 2000; 43: 495-505.
46. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl J Med 2000; 343: 1594-1602.
47. Bekker PJ, Holloway D, Nalanishi A, Arrighi HIM, Dunstan CR. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausale women. J Bone Miner Res 1999; 14(Suppl): S180.
48. Kostenuik PJ, Capparelli C, Morony S, Lacey D, Dunstan C. Osteoprotegerin (OPG) and parathyroid hormone have additive effects on bone mass in aged ovariectomized rats. Osteoprosis Int 2000; 11 (Suppl 2): S206.
49. McHugh KP, Hodivala-Dilke K, Zheng MH et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105: 433-440.
50. Storgard CM, Stupack DG, Jonezyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with alphaVBeta3 antagonist. J Clin Invest 1999; 100: 47-54.
51. Pysklywec MW, Moran EL, Bogoch ER. Zoledronate (CGP 42 446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. J Orthoped Res 1997; 15: 858-861.
52. Francis MD, Hovancik K, Boyce RW. NE-58095: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989; 11: 239-352.
53. Eggelmeijer F, Papapoulos SE, van Paassen HC et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996; 39: 396-402.
54. Sileghem A, Geusens P, Dequeker J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 761-764.
55. Lane NE, Thompson JM, Strewler G, Kinney JH. Intermittent treatment with human parathyroid hormone (hPTH 1-34) increased trabecular bone mass but not connectivity in osteopenic rats. J Bone Miner Res 1996; 10: 1470-1477.
56. Lane NE, Sanchez S, Modin GW, Genant HK, Amaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-1633.